Key Performance Indicators of Clinical Trials in Japan: Implications for Reducing the Drug Lag

Author： Terada Michinori   Narukawa Mamoru   Takeuchi Masahiro  

Publisher： Adis International

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.23, Iss.5-6, 2009-10, pp. : 305-308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The notorious “drug lag“ for oncology drugs in Japan

By Yonemori Kan  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 706-712

Springer Publishing Company

Access to resources Recommend Favorite

Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials

By  

Current Drug Targets, Vol. 14, Iss. 11, 2013-10 ,pp. : 1357-1366

Bentham Science Publishers

Access to resources Recommend Favorite

Hypertension trials should focus on key clinical questions

By  

Inpharma, Vol. 1, Iss. 1535, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Clinical Trials and the New Good Clinical Practice Guideline in Japan: An Economic Perspective

By Ono S.  

PharmacoEconomics, Vol. 18, Iss. 2, 2000-08 ,pp. : 125-141

Adis International

Access to resources Recommend Favorite

A Review of: "Drug Products for Clinical Trials, Second Edition"

By Hickey Jan H.  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 6, 2007-06 ,pp. : 701-701

Informa Healthcare

Access to resources Recommend Favorite